Retreatment of patients with chronic hepatitis C, subtype 3a, and cirrhosis, who previously failed a regimen containing second-generation NS5A inhibitors with sofosbuvir + glecaprevir/pibrentasvir and ribavirin for 16–24 weeks
Journal of Virology · 2025
DOI: 10.1128/jvi.01843-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Virology, 2025. Verfasst von Sergii V Fedorchenko und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Viral Hepatitis and AIDS, The L.V. Gromashevskyi Institute of Epidemiology and Infectious Disease, Kyiv, Ukraine. Hauptthemen laut MEDLINE: Hepatitis C, Chronic, Antiviral Agents, Benzimidazoles, Quinoxalines. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Volgograd State Medical University (VSMU).
Abstract (Originalsprache)
The outcomes of retreatment patients infected with hepatitis C virus genotype 3, cirrhosis, with velpatasvir may be affected by treatment failure with velpatasvir. The efficacy of SOF+GLE/PIB+RIB 16–24 weeks of treatment has been shown. The presence of NS5A resistance-associated substitution mutations, including Y93H, and the number and regimens of the past failed therapy do not influence the likelihood of achieving sustained virological response. When velpatasvir treatment fails, pibrentasvir should be used as the first choice for retreatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Viral Hepatitis and AIDS, The L.V. Gromashevskyi Institute of Epidemiology and Infectious Disease, Kyiv, Ukraine.
ORCID-Profile: Sergii V Fedorchenko
Förderung
- Volgograd State Medical University (VSMU)
Zitieren
APA
Fedorchenko, S. V., Klimenko, Z., Martynovich, T., Solianyk, I., & Suprunenko, T. (2025). Retreatment of patients with chronic hepatitis C, subtype 3a, and cirrhosis, who previously failed a regimen containing second-generation NS5A inhibitors with sofosbuvir + glecaprevir/pibrentasvir and ribavirin for 16–24 weeks. Journal of Virology. https://doi.org/10.1128/jvi.01843-24
Vancouver
Fedorchenko SV, Klimenko Z, Martynovich T, Solianyk I, Suprunenko T. Retreatment of patients with chronic hepatitis C, subtype 3a, and cirrhosis, who previously failed a regimen containing second-generation NS5A inhibitors with sofosbuvir + glecaprevir/pibrentasvir and ribavirin for 16–24 weeks. Journal of Virology. 2025. doi:10.1128/jvi.01843-24
BibTeX
@article{Fedorchenko2025,
author = {Fedorchenko, Sergii V and Klimenko, Zhanna and Martynovich, Tatiana and Solianyk, Iryna and Suprunenko, Tatiana},
title = {Retreatment of patients with chronic hepatitis C, subtype 3a, and cirrhosis, who previously failed a regimen containing second-generation NS5A inhibitors with sofosbuvir + glecaprevir/pibrentasvir and ribavirin for 16–24 weeks},
journal = {Journal of Virology},
year = {2025},
doi = {10.1128/jvi.01843-24}
}
EUVIMED